Canada's New Process For Approval Of Biosimilar Drugs

Law360 (May 11, 2010, 12:29 PM EDT) -- Canada has joined Europe, Japan and several other jurisdictions in providing an administrative pathway for approval of "biosimilar" or "follow-on biologic" drugs. These drugs, known in Canada as "Subsequent Entry Biologics" or "SEBs," consist of biological drugs (proteins, antibodies and other products derived from biological sources) which are similar to previously approved biological drugs. Until now, approval of SEBs has been largely stalled, pending clarification as to how such products would be reviewed — to date, only a single SEB has been approved in Canada....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!